Analysis of 629 pregnancy outcomes in transplant recipients treated with sandimmun

https://doi.org/10.1016/S0041-1345(97)00458-2Get rights and content

Abstract

WE REPORT the course and outcome of 629 pregnancies in patients treated with Sandimmun for transplantation, collected in the Sandoz international database since 1983. Sandimmun has been shown to cross passively the placental blood barrier,1 but no teratogenic effect in animals.2 Regarding the cumulative experience there is no evidence of a teratogenic potential of ciclosporine in humans.

References (3)

  • B.R. Lowenstein et al.

    Am J Obstet Gynecol

    (1988)
There are more references available in the full text version of this article.

Cited by (78)

  • Cyclosporine

    2016, Therapy for Severe Psoriasis
  • Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum

    2016, Clinics in Dermatology
    Citation Excerpt :

    Cyclosporine can diffuse across the placenta, enter fetal circulation, and increase fetal exposure to other drugs.41,42 Congenital malformations have not been observed,42,43 but low birth weight and prematurity have been reported.4,44–46 Although the use of cyclosporine in pregnancy is not recommended, it can be useful in severe disease.

  • Drug safety: Pregnancy rating classifications and controversies

    2016, Clinics in Dermatology
    Citation Excerpt :

    Cyclosporine (Category C) can cross the placenta but has not been associated with congenital malformations. Low birth weight and prematurity have been reported.22,47 It is unclear whether these risks are associated with cyclosporine use or with the underlying disease for which the medication is prescribed.

  • Immunosuppression, rheumatic diseases, multiple sclerosis, and Wilson's disease

    2015, Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Third Edition
View all citing articles on Scopus
View full text